Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270966
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
620±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270966
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-2-oxoazepan-1-yl]-N-methylacetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL526174
Type:
Small organic molecule
Emp. Form.:
C73H104N18O16S2
Mol. Mass.:
1553.848
SMILES:
CC(C)C[C@H](N(C)C(=O)CN1CCCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:103.108,84.87,15.15,63.66,19.27,99.105,wD:4.4,44.46,76.80,30.38,52.62,48.50,(28.01,-21.12,;28.01,-19.59,;29.34,-18.82,;26.69,-18.82,;26.69,-17.29,;25.49,-16.41,;25.47,-14.87,;24.26,-17.34,;24.19,-18.87,;22.84,-16.75,;21.62,-17.68,;21.93,-19.19,;20.95,-20.37,;19.4,-20.34,;18.46,-19.12,;18.84,-17.62,;17.65,-16.64,;16.3,-17.37,;16.31,-18.92,;15.02,-16.5,;15.02,-14.95,;16.35,-14.18,;17.67,-14.96,;19,-14.19,;19.01,-12.65,;17.67,-11.88,;16.34,-12.65,;13.8,-17.39,;12.44,-16.67,;12.45,-15.12,;11.17,-17.53,;11.17,-19.08,;12.5,-19.85,;13.96,-19.36,;14.88,-20.59,;13.99,-21.84,;12.52,-21.38,;9.78,-16.64,;8.42,-17.37,;8.43,-18.91,;7.15,-16.5,;5.94,-17.39,;4.58,-16.67,;4.59,-15.12,;3.3,-17.53,;2.09,-16.64,;.76,-17.42,;.77,-18.97,;-.58,-16.66,;-1.91,-17.44,;-3.27,-16.72,;-3.26,-15.17,;-4.55,-17.58,;-4.55,-19.14,;-3.22,-19.92,;-1.88,-19.14,;-.54,-19.92,;-.54,-21.47,;-1.88,-22.23,;-3.22,-21.47,;-5.77,-16.7,;-7.13,-17.42,;-7.12,-18.97,;-8.41,-16.55,;-9.63,-17.44,;-8.41,-14.99,;-7.07,-14.23,;-7.07,-12.68,;-5.74,-11.96,;-5.7,-10.41,;-4.35,-9.68,;-7.02,-9.61,;-.59,-15.11,;-2.14,-15.13,;-.6,-13.56,;.96,-15.11,;3.3,-19.08,;1.97,-19.85,;4.64,-19.84,;20.24,-16.98,;20.27,-15.44,;27.96,-16.43,;27.96,-14.9,;29.31,-17.16,;30.52,-16.27,;30.52,-14.73,;31.59,-13.64,;33.08,-14.02,;34.16,-12.93,;33.74,-11.45,;34.82,-10.35,;32.25,-11.07,;31.18,-12.16,;31.78,-17.13,;31.79,-18.67,;33.14,-16.41,;33.35,-14.9,;34.87,-14.63,;35.59,-15.99,;34.52,-17.09,;34.78,-18.61,;33.61,-19.59,;36.23,-19.14,;37.44,-18.27,;37.45,-16.72,;38.77,-15.96,;38.71,-19.12,;40.07,-18.39,;38.72,-20.65,)|
Structure:
Search PDB for entries with ligand similarity: